產(chǎn)品訂購信息：
英文名稱  Anti-RANK/CD265 

中文名稱   核轉錄因子NF-κB受體抗體(核因子kB受體活化因子)費用 

別    名  TNFRSF11A; CD265; CD265 antigen; Activator of NFKB; EOF; FEO; mRANK; NFKB activator; ODFR; OFE; Osteoclast differentiation factor receptor; PDB 2; Receptor activator of NF KB; receptor activator of nuclear factor kappa B; TNFRSF 11A; TNFSF11; TRANCE R; RANK receptor.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg 0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應   Human, Mouse, Rat 

產(chǎn)品類型   一抗  

研究領域     細胞生物 轉錄調(diào)節(jié)因子 細胞表面分子

蛋白分子量  predicted molecular weight: 63-70kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human RANK C-terminus 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

核轉錄因子NF-κB受體抗體(核因子kB受體活化因子)費用 產(chǎn)品應用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 CD265 is a member of the tumor necrosis factor receptor (TNFR) family. Human and murine CD265 share 81% amino acid identity in their extracellular domains. CD265 is widely expressed, with highest levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. CD265 is also expressed in dendritic cells. RANK and RANK ligand (RANKL) are important regulators of interactions between T cells and dendritic cells. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Multiple tumor necrosis factor receptor-associated factors (TRAFs) are involved in the signaling of CD265. TRANCE (TNF-related activation-induced cytokines, also known as RANK ligand, osteoprotegerin ligand and osteoclast differentiation factor) is the ligand for CD265. The biological functions mediated by RANK include activation of NFkappaB and cjun N-terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis and lymph node organogenesis. The soluble form of CD265 is able to block TRANCE induced biological activity. The binding of anti-CD265 to cell surface CD265 triggers signal transduction and induces CD265 mediated bioactivity.

Function : Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells.

Subcellular Location : Membrane.

Tissue Specificity : Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland.

DISEASE : Defects in TNFRSF11A are the cause of familial expansile osteolysis (FEO) [MIM:174810]. FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early onset deafness and loss of dentition.

Defects in TNFRSF11A are a cause of Paget disease of bone type 2 (PDB2) [MIM:602080]; also known as familial Paget disease of bone. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull.

Similarity : Contains 4 TNFR-Cys repeats.

核因子kB受體活化因子 RANK

Ki-67(Antigen identified by monoclonal antibody Ki 67) Ki-67 AntigenMulti-class antibodies規(guī)格： 0.5mg

Anti-phospho-Afadin(Ser1718) 磷酸化絲狀肌動蛋白結合蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Phospho-Caspase-9 (Thr125) 磷酸化半胱氨酸蛋白酶9抗體 規(guī)格 0.1ml

小鼠血清封閉液 10ml Gibco原料,2%血清

VEGF-D 英文名稱： 內(nèi)皮生長因子D型抗體 0.1ml

DNA polymerase eta 英文名稱： DNA聚合酶η抗體 0.2ml

Anti-phospho-Afadin(Ser1718) 磷酸化絲狀肌動蛋白結合蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-pre-X protein(NT)/FITC 熒光素標記抗乙毒pre-X蛋白抗體(N端)IgGMulti-class antibodies規(guī)格： 0.2ml

Rabbit Anti-HRP Whole serum 兔抗HRP抗血清Multi-class antibodies規(guī)格： 1ml

白介素10抗體 Anti-IL-10 0.1ml

Donkey anti-Goat IgG whole serum 驢抗羊IgG抗血清 1ml

Phospho-FAK(Tyr576) 英文名稱： 磷酸化粘著斑激酶抗體 0.1ml

Rhesus antibody Rh phospho-PTPN7(Ser246) 磷酸化非受體型蛋白酪氨酸磷酸酶7抗體 規(guī)格 0.1ml

Rabbit Anti-HRP Whole serum 兔抗HRP抗血清Multi-class antibodies規(guī)格： 1ml

SPAG17 英文名稱： 相關抗原17抗體 0.2ml

eIF3H 英文名稱： 真核翻譯起始因子3H抗體 0.1ml

內(nèi)皮生長因子受體2抗體 Anti-VEGFR2/VEGF-R2/Flk1 0.1ml

Anti-TSARG4/FITC 熒光素標記生精細胞凋亡相關基因4抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh phospho-IKKi/IKKe(Thr500) 磷酸化核因子NFκB抑制蛋白激酶i抗體 規(guī)格 0.1ml

CAP2(Adenylyl cyclase-associated protein 2) 環(huán)化酶相關蛋白CAP-2抗原Multi-class antibodies規(guī)格： 0.5mg

MDA-MB-231(ATCC來源), 人癌細胞

Hacat 人永生化角質(zhì)細胞

EPHA4 Others Human 人 EPHA4 人細胞裂解液 (陽性對照)

CM-R115大鼠小梁網(wǎng)細胞完全培養(yǎng)基100mL

周邊細胞培養(yǎng)基PM

EB病毒轉化的人B淋巴細胞;KMY0920 人皮膚肥大細胞完全培養(yǎng)基 100mL

CL-0050Caco-2(人結直腸腺癌細胞)5×106cells/瓶×2

FCGR3A Others Human 人 CD16a / FCGR3A CHO細胞裂解液 (陽性對照)

纖維粘連蛋白-牛源BPF

大額牛腎細胞;BFR-K1 細胞，SP2/0細胞 DU145(細胞)

EB病毒轉化的人B淋巴細胞(彝族);HYL

JAG1 Others Human 人 JAG1 / JAGL1 / CD339 人細胞裂解液 (陽性對照)

核轉錄因子NF-κB受體抗體(核因子kB受體活化因子)費用 MDA-MB-231(ATCC來源), 人癌細胞

Hacat 人永生化角質(zhì)細胞

EPHA4 Others Human 人 EPHA4 人細胞裂解液 (陽性對照)

CM-R115大鼠小梁網(wǎng)細胞完全培養(yǎng)基100mL

周邊細胞培養(yǎng)基PM

EB病毒轉化的人B淋巴細胞;KMY0920 人皮膚肥大細胞完全培養(yǎng)基 100mL

抗體的生物素化標記實驗要點：

1. 核轉錄因子NF-κB受體抗體(核因子kB受體活化因子)費用 如在反應混合液中有疊氮鈉或游離氨基存在,會抑制標記反應。因此,蛋白質(zhì)在反應前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結合位點可能因此被封閉,導致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結合力或活性；

6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結合；

7.交聯(lián)反應后,應充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結合產(chǎn)生競爭作用；

8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導致高本底。

抗體的鑒定：

1）核轉錄因子NF-κB受體抗體(核因子kB受體活化因子)費用 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應,瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應率來表示。交叉反應率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結合率,求出各自在IC50時的濃度,并按公式計算交叉反應率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結合位點與抗原決定簇之間立體構型的合適度決定的。有助于維持抗原抗體復合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。